Heather M. Snyder, Ph.D. Senior Director, Medical & Scientific - - PowerPoint PPT Presentation

Update on Alzheimer’s Research for NARFE

Heather M. Snyder, Ph.D. Senior Director, Medical & Scientific Relations Alzheimer’s Association

2

Types of Dementia

3

What is Alzheimer’s?

• Alzheimer’s is a universally fatal brain disease
• Alzheimer’s has a gradual onset
• Alzheimer’s is progressive, meaning it gets worse
• ver time
• The vast majority of people develop “late onset”

Alzheimer’s dementia (over age 65)

4

Impact of Alzheimer’s Dementia Continues To Grow

$1.1

TRILLION IN 2050

2017 Alzheimer’s Association Facts & Figures

5

6

Alzheimer’s Association Funding the Future

• World’s largest, most impactful

non-profit funder of research; $380M since 1982

• Today, more than $100M active

in 18 countries

• Focus on innovative ideas from

early career investigators

• Emerging areas & gaps

7

Significant Advances Made Possible Because of NARFE!

• Over $12 million funding 71 innovative scientific

projects

• Funding gaps & emerging areas, advancing the

science to the next level

• Research funded spans the full spectrum of science

to better understand & treat Alzheimer’s disease

• NARFE funded researchers are significantly

advancing our understanding of disease, developing tools to improve diagnosis, and exploring diverse avenues for potential therapies

8

8

Both Association Funding and Federal Research Funding are Critical

Association Funding Federal Funding

Association and federal research funding don’t compete… they complement each other

• Quickly deployed
• Precisely targeted
• Global scope
• Higher risk tolerance
• Larger in scale
• Breadth of coverage
• Longer term

sustainability

9

History of Alzheimer’s Disease

tangles plaques

10

Continuum of Alzheimer’s Disease

Normal Alzheimer’s disease

Adapted from Sperling et al. 2011

11

Advances in Early Detection

PET Imaging Structural Neuroimaging Genetics Proteomics Protein production & clearance rates Targeted biochemical Neuropsychometric tests Epidemiology

12

NARFE Investigators Advancing Early Detection

• 2015 award to Min Shi, Ph.D.

(University of Washington) to study changes of tau as potential plasma biomarker of Alzheimer's

• 2011 award to Joseph Goveas, MD

(Medical College of Wisconsin) to investigate different kinds of imaging depressed adults at risk for Alzheimer’s

• 2009 award to Barbara B. Bendlin,

PhD (UW, Madison) to understand changes in brain vascular systems in middle age adults at risk by imaging

13

Pathway to Approval for Drug Development

Adapted from PhRMA Annual report

75

14

• 2011 award to David Cribbs, PhD (UC, Irvine) on links
• f Cerebral Amyloid Angiopathy, inflammation &

hypertension and 2012 award to Michael Agadjanyan, Ph.D. (Institute for Molecular Medicine) on immune response to vaccines; partnering together on a phase 1 trial

• 2014 award to Charbel Moussa, Ph.D. (Georgetown

University) on effects of Nilotinib on tau clearance in Alzheimer’s; funded by NIH and recruiting for participants now

NARFE Investigators Exploring Diverse Potential Therapy Avenues

15

Current Landscape of Clinical Trials for Alzheimer’s & Dementia

Phase I Phase III Phase II

75 Total Trials

• 49 experimental

medications

• 3 medical devise
• 9 diagnostic trials
• 14 experimental

medications for non- AD dementias 112 Total Trials

• 79 experimental

medications

• 7 medical devise
• 6 diagnostic trials
• 20 experimental

medications for non-AD dementias 37 Total Trials

• 14 registration trials
• 5 for agitation or sleep
• 9 academic trials
• 2 medical devise
• 3 diagnostic trials
• 4 trials for non-AD

dementias

As of 2/2017

13 Clinical trials with Computerized Devises for Alzheimer’s and Cognitive Decline for detection and / or cognitive training.

16

Questions On Underlying Biology of Alzheimer’s in Women and in Men

• X/ Y chromosomes genetic links

disease related biology

• Differences in brain function &

networks as it relates to disease

• Links of hormone levels (i.e.

perimenopause) & energy metabolisms (i.e. shift from glucose to ketone energy usage)

• Lifestyle factors (i.e. stress,

metabolism, sleep) related to risk and/or reduced risk

17

Underlying Biology of Alzheimer’s in Women and in Men

• X/ Y chromosomes genetic links

disease related biology

• Differences in brain function &

networks as it relates to disease

• Links of hormone levels (i.e.

perimenopause) & energy metabolisms (i.e. shift from glucose to ketone energy usage)

• Lifestyle factors (i.e. stress,

metabolism, sleep) related to risk and/or reduced risk

18

Continuum of Alzheimer’s Disease

Normal Alzheimer’s disease

Adapted from Sperling et al. 2011

19

Collaboration for Alzheimer’s Prevention

20

What should I be doing now?

21

If we delay onset of Alzheimer’s by 5 years…

22

Thank you You are making a difference towards seeing a World without Alzheimer’s!

23